Inebilizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD19 |
| Clinical data | |
| Pronunciation | /ɪˌnɛbɪˈlɪzjʊmæb/ ih-NEH-bih-LIZ-yuum-ab |
| Trade names | Uplizna |
| Other names | inebilizumab-cdon, AMG 335, HZN-551, VIB-551, MEDI-551 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a625074 |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Immunosuppressive drug |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6504H10080N1732O2044S44 |
| Molar mass | 146652.90 g·mol−1 |
Inebilizumab, sold under the brand name Uplizna, is a medication used for the treatment of neuromyelitis optica spectrum disorder, immunoglobulin G4-related disease, and generalized myasthenia gravis. Inebilizumab is a humanized monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody).
The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.
Inebilizumab was approved for medical use in the United States in June 2020, in the European Union in April 2022, and in Canada in December 2023. The US Food and Drug Administration considers it to be a first-in-class medication.